Listed

Lakefront Biotherapeutics NV: Form 20-F for the period ended Dec 31, 2019

Filed with the SEC on Mar 27, 2020 and accepted by EDGAR at Mar 27, 2020, 16:41 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2019-01-01 to 2019-12-31EUR 845.0mifrs-full:Revenue
Operating income12 months2019-01-01 to 2019-12-31EUR 370.3mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2019-01-01 to 2019-12-31EUR 214.0kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2019-01-01 to 2019-12-31EUR 149.8mifrs-full:ProfitLossAttributableToOwnersOfParent
Diluted EPS12 months2019-01-01 to 2019-12-31EUR 2.49ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2019-01-01 to 2019-12-31EUR 2.60ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2019-01-01 to 2019-12-31EUR 3.21bnifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2019-01-01 to 2019-12-31EUR 22.4mifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2019-12-31$656.9mifrs-full:CashAndCashEquivalents
Current assetsAt period end2019-12-31EUR 5.87bnifrs-full:CurrentAssets
Total assetsAt period end2019-12-31EUR 6.07bnifrs-full:Assets
Current liabilitiesAt period end2019-12-31EUR 571.8mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2019-12-31EUR 3.19bnifrs-full:Liabilities
Shareholders' equityAt period end2019-12-31EUR 2.88bnifrs-full:Equity
Shares outstandingAt period end2019-12-3164,666,802 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001558370-20-003270. Last ingested by Listed: Nov 4, 2026, 10:00 ET. Listed shows no prices and gives no investment advice.